| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2018: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
The anti-tumor activity of Sendai virus envelope (HVJ-E) is dependent of RIG-I and MAVS signaling pathway, which induces anti-tumor immunity and cancer-selective cell death. We identified IRF7 plays a pivotal role for HVJ-E-activated anti-tumor activity. RNA seq. analysis was performed to elucidate gene expression pattern in melanoma samples isolated from HVJ-E-treated patients. Both T cell activation and exhaustion markers were up-regulated. Then, we obtained melanoma tissue derived from metastatic lymph node of patients resistant to anti-PD-1 therapy. PDX mice were constructed and treated with HVJ-E by intratumoral injection. Tumors were significantly suppressed by the treatment. These results suggest that combination of HVJ-E with anti-PD-1 antibody will provide more effective cancer therapy to cancer patients.
|
